


DISCOVER



HOW WE AIM TO
TRANSFORM RADIATION
THERAPY IN CANCER

The Science of Selective Dismutase Mimetics

Selective dismutase mimetics rapidly and specifically convert superoxide to hydrogen peroxide and oxygen^{1,2}



Selective Dismutase Mimetics Pipeline

PATIENT POPULATION	THERAPEUTIC TARGET	PHASE 1	PHASE 2	PHASE 3	TRIAL STATUS
 Head & Neck Cancer	Radiation-induced severe oral mucositis	ROMAN: Avasopasem vs placebo			COMPLETED ENROLLMENT
		EUSOM: Avasopasem			COMPLETED ENROLLMENT
 Lung Cancer	Radiation-induced esophagitis	AESOP: Avasopasem			COMPLETED ENROLLMENT
	Increased SBRT efficacy	GRECO-1: Rucosopasem vs placebo			RECRUITING
 Pancreatic Cancer	Increased SBRT efficacy	GRECO-2: Rucosopasem vs placebo			RECRUITING
Please see clinicaltrials.gov for more information on our trials		Avasopasem manganese (GC4419) Rucosopasem manganese (GC4711)			

SBRT=stereotactic body radiation therapy.



Lung Cancer

Investigating Rucosopasem for Lung Cancer Efficacy



GRECO-1

Phase 1/2 study of rucosopasem in combination with SBRT for early stage non-small cell lung cancer

Key inclusion criteria:

- Adult patients with early stage peripheral or centrally localized NSCLC
- ECOG performance status 0-3

Key exclusion criteria:

- Adult patients with confirmed nodal and/or distant disease (including brain)
- Patients with peripheral lesions (≤ 1 cm)

1:1 randomization

SBRT + **rucosopasem** (IV) before each fraction of SBRT

SBRT + **placebo** (IV) before each fraction of SBRT

Primary endpoint (Phase 2):

Percentage of patients with complete or partial in field tumor response based on RECIST 1.1 at 6 months post SBRT

Rucosopasem manganese (GC4711)

ECOG=Eastern Cooperative Oncology Group; IV=intravenous; NSCLC=non-small cell lung cancer; SBRT=stereotactic body radiation therapy.

Reference: <https://clinicaltrials.gov/ct2/show/NCT04476797>



Pancreatic Cancer

Investigating Rucosopasem for Pancreatic Cancer Efficacy



GRECO-2

Phase 2b study of rucosopasem in combination with SBRT for nonmetastatic pancreatic cancer

Key inclusion criteria:

- Adult patients with borderline resectable or unresectable pancreatic cancer
- ECOG performance status 0–2

Key exclusion criteria:

Patients with documented metastatic disease

≥ 6 weeks of chemotherapy

Screening and chemotherapy response evaluation

1:1 randomization

5 days SBRT + rucosopasem

5 days SBRT + placebo

Response evaluation

Judged unresectable

Optional chemo

Judged resectable

Surgical exploration

Optional chemo

Primary EndPoint:
Overall Survival

Rucosopasem manganese (GC4711)

SBRT=stereotactic body radiation therapy.

Reference: <https://clinicaltrials.gov/ct2/show/NCT04698915>



WHAT'S NEXT IN
RADIATION THERAPY

VISIT US AT
GALERATX.COM

